Replimune (REPL) Assets Average (2018 - 2025)
Replimune's (REPL) quarterly Assets Average came in at $361.5 million in Q4 2025, down 34.38% year-on-year from $550.9 million in Q4 2024, and down 15.82% quarter-over-quarter from $429.5 million in Q3 2025.
Replimune (REPL) Assets Average (2018 - 2025) Analysis & Trends
Replimune has disclosed Assets Average across 8 years of filings, most recently posting $361.5 million for Q4 2025.
- Assets Average for Q4 2025 came in at $361.5 million, down 34.38% year-over-year; the trailing twelve-month figure through Dec 2025 was $361.5 million (down 34.38% YoY), and the FY2025 annual result was $519.5 million, down 8.4% from the prior year.
- Assets Average came in at $361.5 million for Q4 2025 at Replimune, down from $429.5 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $662.6 million in Q1 2023 to a low of $361.5 million in Q4 2025.
- The 5-year median for Assets Average is $515.1 million (2021), against an average of $520.9 million.
- Across the five-year window, Assets Average jumped 127.5% in 2021 and tumbled 34.38% in 2025, its largest moves.
- Replimune's Assets Average stood at $494.4 million in 2021, then increased by 12.73% to $557.3 million in 2022, then decreased by 1.73% to $547.7 million in 2023, then increased by 0.59% to $550.9 million in 2024, then sank by 34.38% to $361.5 million in 2025.
- The last three Assets Average figures came in at $361.5 million (Q4 2025), $429.5 million (Q3 2025), and $510.4 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | 33.42 Mn |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | 795.91 Mn |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 13.04 Mn |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | 1.72 Bn |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 40.89 Mn |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | 26.03 Mn |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | 10.06 Mn |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | 26.06 Bn |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | 660.38 Mn |
| 10 | Replimune | 780.01 Mn | 510.88 Mn | - | 361.52 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 361.52 Mn |
| Sep 30, 2025 | 429.48 Mn |
| Jun 30, 2025 | 510.42 Mn |
| Mar 31, 2025 | 577.48 Mn |
| Dec 31, 2024 | 550.92 Mn |
| Sep 30, 2024 | 516.58 Mn |
| Jun 30, 2024 | 511.34 Mn |
| Mar 31, 2024 | 510.33 Mn |
| Dec 31, 2023 | 547.66 Mn |
| Sep 30, 2023 | 583.14 Mn |
| Jun 30, 2023 | 625.24 Mn |
| Mar 31, 2023 | 662.57 Mn |
| Dec 31, 2022 | 557.32 Mn |
| Sep 30, 2022 | 447.76 Mn |
| Jun 30, 2022 | 460.31 Mn |
| Mar 31, 2022 | 473.24 Mn |
| Dec 31, 2021 | 494.37 Mn |
| Sep 30, 2021 | 513.59 Mn |
| Jun 30, 2021 | 533.41 Mn |
| Mar 31, 2021 | 551.15 Mn |